Providers responded to the statement, “I feel comfortable ordering a pharmacogenetic test to predict risk of adverse events or likelihood of response (e.g., CYP2C9/VKORC1 and warfarin therapy)”. Percentages responding ‘agree’ or ‘strongly agree’ were adjusted for respondents' role, age and gender.
OB/GYN: Obstetrics/gynecology; PGx: Pharmacogenomic.